Tolerability and safety of rituximab (MabThera®)

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Davis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636

Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., & Keating, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2165 · Cited by 586

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

Ghielmini, M. (2004) · Blood · doi:10.1182/blood-2003-10-3411 · Cited by 570

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Colombat, P. (2001) · Blood · doi:10.1182/blood.v97.1.101 · Cited by 524

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

Edwards, J. C. W., & Cambridge, G. (2001) · Rheumatology · doi:10.1093/rheumatology/40.2.205 · Cited by 523

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2153 · Cited by 508

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Velasquez, W. S., McLaughlin, P., Tucker, S., Hagemeister, F. B., Swan, F., Rodriguez, M. A., Romaguera, J., Rubenstein, E., & Cabanillas, F. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1169 · Cited by 430

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

Hainsworth, J. D., Litchy, S., Burris, H. A., Scullin, D. C., Corso, S. W., Yardley, D. A., Morrissey, L., & Greco, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.674 · Cited by 416

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D. A., Teruya-Feldstein, J., Gencarelli, A., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3911 · Cited by 406

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

Byrd, J. C. (2005) · Blood · doi:10.1182/blood-2004-03-0796 · Cited by 404

Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008389119525 · Cited by 368

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., & Grillo-López, A. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.020 · Cited by 366

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

Hainsworth, J. D., Litchy, S., Barton, J. H., Houston, G. A., Hermann, R. C., Bradof, J. E., & Greco, F. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.027 · Cited by 351

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 345

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Moskowitz, C. H., Bertino, J. R., Glassman, J. R., Hedrick, E. E., Hunte, S., Coady-Lyons, N., Agus, D. B., Goy, A., Jurcic, J., Noy, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3776 · Cited by 302

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

Alas, S., & Bonavida, B. (2001) · PubMed · Cited by 293

Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab

Davis, T. A., White, C. A., Grillo-López, A. J., Velasquez, W. S., Link, B. K., Maloney, D. G., Dillman, R. O., Williams, M. E., Mohrbacher, A., Weaver, R. L., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1851 · Cited by 290

Rituximab treatment results in impaired secondary humoral immune responsiveness

van der Kolk, L. E., Baars, J. W., Prins, M. H., & van Oers, M. H. J. (2002) · Blood · doi:10.1182/blood.v100.6.2257 · Cited by 284

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Davis, T. A., Czerwinski, D. K., & Levy, R. (1999) · PubMed · Cited by 267

Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance

Byrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264

Infectious and immunosuppressive complications of purine analog therapy.

Cheson, B. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2431 · Cited by 260

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257

The mechanisms of action of rituximab in the elimination of tumor cells

Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy

Westhoff, T. H., Jochimsen, F., Schmittel, A. H., Stöffler-Meilicke, M., Schäfer, J.-H., Zidek, W., Gerlich, W. H., & THIEL, E. (2003) · Blood · doi:10.1182/blood-2003-05-1403 · Cited by 203

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., Stockerl-Goldstein, K. E., Johnston, L. J., Wong, R. M., Shizuru, J. A., & Horning, S. J. (2004) · Blood · doi:10.1182/blood-2003-04-1257 · Cited by 200

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin

Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191

CD79: A Review

Chu, P. G., & Arber, D. A. (2001) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/00129039-200106000-00001 · Cited by 190

Neutropenia in Patients Treated with Rituximab

(2003) · New England Journal of Medicine · doi:10.1056/nejm200306263482620 · Cited by 189

Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma

Gluck, W. L., Hurst, D., Yuen, A., Levine, A. M., Dayton, M. A., Gockerman, J. P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1087-3 · Cited by 166

Interstitial Pneumonitis Related to Rituximab Therapy

Burton, C. H., Kaczmarski, R. S., & Jan-Mohamed, R. (2003) · New England Journal of Medicine · doi:10.1056/nejm200306263482619 · Cited by 152

Delayed‐onset neutropenia associated with rituximab therapy

Chaiwatanatorn, K., Lee, N., Grigg, A., Filshie, R., & Firkin, F. C. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04385.x · Cited by 149

Safety of rituximab therapy during the first trimester of pregnancy: a case history

Kimby, E. K., Sverrisdóttir, Á., & Elinder, G. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00214.x · Cited by 142

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma

Friedberg, J. W., Neuberg, D. S., Gribben, J. G., Fisher, D. C., Canning, C. M., Koval, M. A., Poor, C. M., Green, L. M., Daley, J. F., Soiffer, R. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03535.x · Cited by 140

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

Jilani, I. B., O'Brien, S. M., Manshuri, T., Thomas, D. A., Thomázy, V. A., Imam, M., Naeem, S., Verstovšek, S., Kantarjian, H. M., Giles, F. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0055 · Cited by 136

OKT3 first-dose reaction: Association with T cell subsets and cytokine release

Gaston, R. S., Deierhoi, M. H., Patterson, T., Prasthofer, E., Julian, B. A., Barber, W. H., Laskow, D. A., Diethelm, A. G., & Curtis, J. J. (1991) · Kidney International · doi:10.1038/ki.1991.18 · Cited by 134

Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review

Kennedy, G., Tey, S., Cobcroft, R., Marlton, P. V., Cull, G., Grimmett, K., Thomson, D. B., & Gill, D. S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03843.x · Cited by 121

Stevens–Johnson syndrome after treatment with rituximab

Lowndes, S. A., Darby, A., Mead, G. M., & Lister, A. T. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf350 · Cited by 120

Rituximab in indolent lymphoma: the single-agent pivotal trial.

McLaughlin, P. J., Hagemeister, F. B., & Grillo-López, A. J. (1999) · PubMed · Cited by 116

Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments

Cattaneo, C. M., Spedini, P., Casari, S., Re, A., Tucci, A., Borlenghi, E., Ungari, M., Ruggeri, G. M., & Rossi, G. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500473113 · Cited by 116

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis

Foran, J. M., Norton, A. J., Micallef, I. N. M., Taussig, D. C., Amess, J. A. L., Rohatiner, A. Z. S., & Lister, T. A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03019.x · Cited by 113

Standard‐dose anti‐CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study

Itälä, M., Ch, G., Kimby, E. K., Juvonen, E., Tjønnfjord, G. E., Karlsson, K., & Remes, K. (2002) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2002.02786.x · Cited by 106

Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)

D'Arcy, C. A., & Mannik, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1717::aid-art299>3.0.co;2-c · Cited by 96

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

Lemieux, B., Tartas, S., Traullé, C., Espinouse, D., Thiéblemont, C., Bouafia, F., Alhusein, Q., Antal, D., Salles, G., & Coiffier, B. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704467 · Cited by 91

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

Papadaki, T., Σταματόπουλος, Κ., Stavroyianni, N., Paterakis, G. S., Phisphis, M., & Stefanoudaki-Sofianatou, K. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00183-7 · Cited by 86

Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma

Alexandrescu, D. T., Dutcher, J. P., O’Boyle, K., Albulak, M., Oiseth, S. J., & Wiernik, P. H. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001697359 · Cited by 73

Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment

Hellerstedt, B. A., & Ahmed, A. A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg488 · Cited by 69

Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.

Alas, S., Bonavida, B., & Emmanouilides, C. E. (2000) · PubMed · Cited by 68

Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)

Swords, R., Power, D., Fay, M., O’Donnell, R., & Murphy, P. T. (2004) · American Journal of Hematology · doi:10.1002/ajh.20135 · Cited by 67

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., & van Oers, M. H. J. (2003) · Leukemia · doi:10.1038/sj.leu.2402995 · Cited by 64

Rituximab in B-Cell chronic lymphocytic leukemia

Lin, T. S., Lucas, M. S., & Byrd, J. C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00239-2 · Cited by 61

Loss of CD20 expression in relapsed lymphomas after rituximab therapy

Haidar, J. H., Shamseddine, A. I., Salem, Z. M. K., et al. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00007.x · Cited by 59

Management of acute tumor lysis syndrome

Sallan, S. E. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90255-6 · Cited by 54

Re-evaluation of Benefits of BRCA1/2 Testing

Knell, E. R., Presant, C. A., Grann, V. R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1962 · Cited by 52

Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis

Kanelli, S., Ansell, S. M., Habermann, T. M., Inwards, D. J., Tuinstra, N., & Witzig, T. E. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190127502 · Cited by 51

Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody

Maeda, T., Yamada, Y., Tawara, M., et al. (2001) · International Journal of Hematology · doi:10.1007/bf02982552 · Cited by 42

Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab

Dillman, R. O. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00235-5 · Cited by 38

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.

Hernández, J., Diloy, R., Salat, D., del Rio, N., Martínez, X., & Castellví, J. B. (2003) · PubMed · Cited by 33

Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia

Savage, D. G., Cohen, N. S., Hesdorffer, C. S., Heitjan, D. F., Oster, M. W., Garrett, T. J., Bar, M. H., Prete, S. D., March, R., Lonberg, M., et al. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000046958 · Cited by 31

Cutaneous B‐cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy

Clarke, L. E., Bayerl, M. G., Ehmann, W. C., & Helm, K. F. (2003) · Journal of Cutaneous Pathology · doi:10.1034/j.1600-0560.2003.00078.x · Cited by 24

Successful Treatment of Aggressive HIV-associated Non-Hodgkin's Lymphoma with Combination Chemotherapy, Biotherapy with Rituximab and HAART: Presentation of a Therapeutic Option

Klepfish, A., Schattner, A., Shvidel, L., Shtalrid, M., Haran, M. Z., Bentwich, Z., & Berrébi, A. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000060537 · Cited by 20

Agranulocytosis unresponsive to growth factors following rituximab in vivo purging

Rose, A. L., Forsythe, A. M., & Maloney, D. G. (2003) · Blood · doi:10.1182/blood-2003-02-0450 · Cited by 20

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638

EFNS guidelines on diagnosis and management of neuromyelitis optica

Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., & Hemmer, B. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03066.x · Cited by 461

Rheumatoid arthritis-associated lung disease

Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015) · European Respiratory Review · doi:10.1183/09059180.00008014 · Cited by 366

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia

Barmettler, S., Ong, M.-S., Farmer, J. R., Choi, H., & Walter, J. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4169 · Cited by 357

A review of the current use of rituximab in autoimmune diseases

Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314